DDInter1254 DDInter856
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Nabumetone {u} (Compound) resembles {v} (Compound) Melatonin
Nabumetone {u} (Compound) binds {v} (Gene) MPO
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
Nabumetone {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nabumetone {u} (Compound) downregulates {v} (Gene) DNAJA3
Nabumetone {u} (Compound) causes {v} (Side Effect) Pruritus
Nabumetone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alteplase
Nabumetone (Compound) resembles Naproxen (Compound)
Nabumetone (Compound) resembles Melatonin (Compound)
Nabumetone (Compound) binds MPO (Gene)
Nabumetone (Compound) palliates osteoarthritis (Disease)
Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Nabumetone (Compound) downregulates DNAJA3 (Gene)
Nabumetone (Compound) causes Pruritus (Side Effect)
Nabumetone may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Alteplase